Rufinamide
23 NDCs across 11 manufacturers|20 Generic,3 Brand
Rufinamide is used to treat seizures, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 14, 2008, and the first generic was approved May 16, 2016. FDA's Orange Book lists 25 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $47 million on Rufinamide across 28,000 claims for 2,765 beneficiaries.
Rufinamide is available as 23 NDCs from 11 manufacturers (20 generic, 3 brand), with NADAC prices from $0.88 to $25.18 per EA — the most expensive product costs about 29× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
23
20G / 3B
Manufacturers
11
competing in market
Price Spread
$0.88 – $25.18
per EA, 14 of 23 NDCs
7d Activity
avg +0.4% WoW · of 23 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Eisai Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
11 manufacturers producing RUFINAMIDE(1 pricing outlier)
Frequently Asked Questions
What is Rufinamide used to treat?
Rufinamide is used to treat seizures, per the National Library of Medicine's MED-RT classification.
When did Rufinamide become available as a generic?
FDA approved the first generic Rufinamide (ANDA) on May 16, 2016. The Orange Book currently lists 25 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rufinamide?
In 2024, Medicare Part D spent $47 million on Rufinamide across 28,000 claims for 2,765 beneficiaries.
How many Rufinamide products are on the market?
The Rufinamide drug market contains 23 NDCs from 11 manufacturers — 20 generic and 3 brand products.
What is the price range for Rufinamide?
NADAC reference prices for Rufinamide range from $0.8810 to $25.1826 per EA — the most expensive product costs about 29× the cheapest. 9 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Rufinamide cheaper than brand?
The average generic NADAC for Rufinamide is $1.1362 per EA, versus $18.8965 for brand-labeled products — brand versions average about 17× the generic price.
Which manufacturers make Rufinamide?
11 manufacturers list Rufinamide in NADAC. Ranked by number of NDCs, the largest are Eisai Inc. (3), Aurobindo Pharma Limited (3), Hikma Pharmaceuticals USA Inc. (3), Camber Pharmaceuticals Inc. (3), Lupin Pharmaceuticals Inc. (3).
How has the price of Rufinamide changed recently?
Over the past 7 days, 6 Rufinamide NDCs rose and 15 fell, with a market-wide average change of +0.4%.